Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma
Pediatric neuroblastoma in its advanced stage (st. IV) is usually lethal. 70% of the affected children die. 50% of the children show upon diagnosis metastasis or a genetic amplification of the oncogene N-myc. This group has a poor prognosis and a 5-year survival rate of only 33%. A drawback of the current standard therapy is the poor efficacy accompanied with severe side effects. Therefore a new treatment of neuroblastoma with a different antitumoral mode of action than the traditional cytotoxics is urgently required.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
